
Beta-Cell
Beta-Cell is developing a cell therapy for diabetes patients that experience no benefit from existing treatments. The company developed a quality controlled proprietary cell product and has an extensive track record in diabetes models (both in vitro as in vivo). Beta-Cell has been funded by VLAIO and Europe and by private investors with the Belgian-based Group Machiels as main shareholder.